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Acute hyperglycemia abolishes 
cardioprotection by remote ischemic 
perconditioning
Tamás Baranyai1, Csilla Terézia Nagy1, Gábor Koncsos1, Zsófia Onódi1, Melinda Károlyi‑Szabó1, András Makkos1, 
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Abstract 
Background: Remote ischemic perconditioning (RIPerC) has a promising therapeutic insight to improve the prog‑
nosis of acute myocardial infarction. Chronic comorbidities such as diabetes are known to interfere with condition‑
ing interventions by modulating cardioprotective signaling pathways, such as e.g., mTOR pathway and autophagy. 
However, the effect of acute hyperglycemia on RIPerC has not been studied so far. Therefore, here we investigated the 
effect of acute hyperglycemia on cardioprotection by RIPerC.
Methods: Wistar rats were divided into normoglycemic (NG) and acute hyperglycemic (AHG) groups. Acute hyper‑
glycemia was induced by glucose infusion to maintain a serum glucose concentration of 15–20 mM throughout the 
experimental protocol. NG rats received mannitol infusion of an equal osmolarity. Both groups were subdivided into 
an ischemic (Isch) and a RIPerC group. Each group underwent reversible occlusion of the left anterior descending 
coronary artery (LAD) for 40 min in the presence or absence of acute hyperglycemia. After the 10‑min LAD occlusion, 
RIPerC was induced by 3 cycles of 5‑min unilateral femoral artery and vein occlusion and 5‑min reperfusion. After 
120 min of reperfusion, infarct size was measured by triphenyltetrazolium chloride staining. To study underlying sign‑
aling mechanisms, hearts were harvested for immunoblotting after 35 min in both the NG and AHG groups.
Results: Infarct size was significantly reduced by RIPerC in NG, but not in the AHG group (NG + Isch: 46.27 ± 5.31 % 
vs. NG + RIPerC: 24.65 ± 7.45 %, p < 0.05; AHG + Isch: 54.19 ± 4.07 % vs. 52.76 ± 3.80 %). Acute hyperglycemia per 
se did not influence infarct size, but significantly increased the incidence and duration of arrhythmias. Acute hyper‑
glycemia activated mechanistic target of rapamycine (mTOR) pathway, as it significantly increased the phosphoryla‑
tion of mTOR and S6 proteins and the phosphorylation of AKT. In spite of a decreased LC3II/LC3I ratio, other mark‑
ers of autophagy, such as ATG7, ULK1 phopsphorylation, Beclin 1 and SQSTM1/p62, were not modulated by acute 
hyperglycemia. Furthermore, acute hyperglycemia significantly elevated nitrative stress in the heart (0.87 ± 0.01 vs. 
0.50 ± 0.04 µg 3‑nitrotyrosine/mg protein, p < 0.05).
Conclusions: This is the first demonstration that acute hypreglycemia deteriorates cardioprotection by RIPerC. The 
mechanism of this phenomenon may involve an acute hyperglycemia‑induced increase in nitrative stress and activa‑
tion of the mTOR pathway.
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Background
Remote ischemic conditioning (RIC) is a clinically appli-
cable cardioprotective intervention induced by intermit-
tent occlusions and reperfusions on a remote organ e.g., 
a limb. It is proved to be highly effective against acute 
ischemia/reperfusion injury in animal models [1–4]. Due 
to its accessibility and simplicity, RIC was rapidly trans-
lated into different clinical situations of cardiovascular 
events [1, 3]. Despite the promising results of preceding 
animal studies, its infarct size reducing potential is equiv-
ocal in acute coronary syndrome patients [1]. Moreover, 
the largest randomized multi-center clinical trial includ-
ing 1612 patients [Effect of remote ischemic precon-
ditioning on clinical outcomes in patients undergoing 
coronary artery bypass graft surgery (ERICCA)] did not 
show any benefit on major adverse cardiac and cerebral 
events [5]. Reasons of these discrepancies are yet to be 
determined.
It has been shown that comorbidities (e.g., diabetes 
mellitus, hyperlipidemia) and comedications (e.g., angio-
tensin-converting enzyme inhibitors, statins) deteriorate 
cardioprotective effects of various conditioning stimuli 
(e.g., ischemic preconditioning and postconditioning) [2, 
6, 7], however, only a few papers examined these chronic 
confounding factors in RIC so far. For example, Kiss et al. 
showed that remote ischemic perconditioning, i.e., RIC 
applied during a prolonged myocardial ischemia, (RIP-
erC) is not effective in a rat model of type 1 diabetes 
mellitus [8]. Similarly, the cardioprotective effect of RIC 
has been shown to be deteriorated in patients with type 
1 and 2 diabetes mellitus [9]. Apart from being a major 
component of chronic metabolic diseases, hyperglycemia 
may also occur in acute situations (e.g., sympathetic over-
activation during acute coronary syndrome) [10]. Hyper-
glycemia in nondiabetic patients (where hyperglycemia 
is unlikely to persist) is generally associated with adverse 
outcomes after an acute myocardial infarction [11]. It is 
not known whether this acute hyperglycemia is the cause 
of adverse outcomes or it only reflects the severity of the 
acute myocardial infarction [10]. Furthermore, it has 
been shown that hyperglycemia inhibits cardioprotec-
tion conferred by ischemic preconditioning or cardio-
protection by various pharmacological agents [12–14]. 
However, it is not known whether acute hyperglycemia 
without pre-existing impaired glucose metabolism hin-
ders cardioprotection by RIPerC.
Therefore, we aimed to investigate whether RIPerC-
induced cardioprotection is affected by acute hyperglyce-
mia and demonstrated for the first time in the literature 
that RIPerC failed to exert cardioprotection in acute 
hyperglycemia without pre-existing systemic metabolic 
disturbance. Furthermore, we have also shown that acute 
hyperglycemia increased nitrative stress and activated 
cardiac mechanistic target of rapamycine (mTOR) path-
way, but not cardiac autophagy, which might be involved 
in the mechanism of the lost cardioprotection by RIPerC 
in acute hyperglycemia.
Methods
This investigation conforms to the Guide for the Care 
and Use of Laboratory Animals published by the US 
National Institutes of Health (NIH publication No. 
85–23, revised 1996), to the EU Directive (2010/63/EU) 
and was approved by the animal ethics committee of the 
Semmelweis University, Budapest, Hungary.
In vivo experiments (Fig. 1)
220–280  g male Wistar rats were anaesthetized with 
60 mg/kg pentobarbital. Since autophagy and cardiopro-
tection are markedly influenced by fasting [15–17], ani-
mals were not fasted before enrolment. The absence of 
pedal reflex was considered as deep surgical anaesthesia. 
Electric activity of the heart was monitored (AD Instru-
ments, Bella Vista, Australia). Blood pressure was meas-
ured in the carotid artery (AD Instruments, Bella Vista, 
Australia). Body temperature was maintained with a heat 
pad at physiological temperature (35.8–38.3  °C). Rats 
were ventilated with 10 mL/kg stroke volume at rate of 80 
strokes/min (Ugo-Basile, Gemonio, Italy).
Rats were randomized into 2 groups: control normo-
glycemic (NG), and acute hyperglycemic (AHG). AHG 
animals received 50  % dextrose (vWR, Radnor, PA, US) 
infusion via tail vein from the start of the experimen-
tal protocol. A blood glucose level of 15–20  mM was 
reached within 5 min by an infusion rate of 150 µL/min. 
Then infusion rate was adjusted to maintain blood glu-
cose levels between 15 and 20 mM throughout the entire 
protocol (0–60 µL/min, with an average of 50 µL/min), 
which was measured every 15 min (Accu-Check, Roche, 
Basel, Switzerland). In NG animals, an equal osmolarity, 
46 % mannitol solution was administered (vWR, Radnor, 
PA, US, induction rate: 150 µL/min for 5  min, then 50 
µL/min).
After 35 min of in vivo perfusion, half of the animals 
from normoglycemic and acute hyperglycemic groups 
were sacrificed, and hearts were excised, immersed 
readily in ice-cold Krebs-Henseleit solution until they 
were mounted. They were then perfused in Langendorff 
mode for 1 min with oxygenated (95 % oxygen/5 % CO2 
gas mixture) Krebs-Henseleit solution (118  mM NaCl, 
4.7 mM KCl, 1.2 mM MgSO4, 1.25 mM CaCl2, 1.2 mM 
KH2PO4, 25 mM NaHCO3 and 11 mM glucose) at 37 °C 
to wash out blood, as described earlier [18]. Then the 
hearts were snap-frozen in liquid nitrogen and stored 
at −80  °C until further experiments. The other half of 
the animals were further randomized into four groups: 
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(1) control ischemic with normoglycemia (NG +  Isch), 
(2) remote ischemic perconditioned with NG 
(NG + RIPerC), (3) ischemic with acute hyperglycemia 
(AHG +  Isch), and (4) remote ischemic perconditioned 
with acute hyperglycemia (AHG + RIPerC). At 35′ of the 
study protocol, left anterior descending coronary artery 
(LAD) was occluded with a 6–0 polypropylene suture 
via median thoracotomy for 40 min. Occlusion was con-
firmed by ST segment elevation, arrhythmias and paling 
of the occluded area. RIPerC was induced by 3 cycles of 
5 min occlusion and 5 min reperfusion of the right fem-
oral vessels starting after 10 min of the LAD occlusion. 
Both the femoral artery and vein were occluded with 
a metal vessel clamp after isolation of the vessels from 
the surrounding connective tissue and femoral nerve. 
At the end of the 40  min index ischemia, reperfusion 
was induced by loosening the suture. At the end of the 
120  min reperfusion, hearts were harvested for infarct 
size evaluation.
Infarct size measurement
Hearts were excised after 120  min of reperfusion, per-
fused for 1  min with oxygenated Krebs-Henseleit solu-
tion in Langendorff mode. LAD was reoccluded, and the 
area at risk was negatively stained with Evans blue. For 
the assessment of viable myocardial tissue, 2  mm thick 
slices were cut and incubated in 1 % triphenyltetrazolium 
chloride (Sigma, St. Louis, MO, US) at 37 °C for 15 min. 
Slices were fixed in 4 % formalin for 16 h, weighed and 
scanned. Planimetric analyses were performed by two 
independent investigators with InfarctSize 2.4b software 
(Pharmahungary Group, Budapest, Hungary). Area at 
risk was expressed as the proportion of the left ventricu-
lar mass, and infarct size as the proportion of the area at 
risk mass.
Arrhythmia analysis
An electrocardiogram was recorded throughout the 
entire experiment. Arrhythmia analysis was performed 
according to the Lambeth conventions, and arrhythmia 
incidence and duration scores were calculated [19].
Myocardial 3‑nitrotyrosine measurement
Free myocardial 3-nitrotyrosine was measured from left 
ventricular samples harvested at 35′ with 3-nitrotyrosine 
ELISA (Cayman, Ann Arbor, MI, US) according to the 
manufacturer’s protocol.
Western blot
Left ventricular tissue was homogenized in radioimmuno-
precipitation assay buffer (Cell Signaling, Danvers, MA, 
US) supplemented with protease inhibitor (Roche, Basel, 
Switzerland), sodium fluoride (Sigma, St. Louis, MO, US) 
and PMSF (Sigma, St. Louis, MO, US). Protein concentra-
tion of the homogenates was measured by Bicinchoninic 
Acid Assay kit (Thermo Fisher Scientific, Waltham, MA, 
US). Equal amount of protein (25  µg) was mixed with 
reducing 5×  Laemmli buffer, loaded and separated in 
a 4–20  % precast Tris–glycine SDS polyacrilamide gel 
(Bio-Rad, Hercules, CA, US). Proteins were transferred 
onto a polyvinylidene difluoride membrane (Bio-Rad, 
Hercules, CA, US) at 350  mA for 2  h. Proper transfer 
was visualized with Ponceau staining (Sigma, St. Louis, 
MO, US). Membranes were blocked with 5 % BSA (Santa 
Cruz Biotechnology, Dallas, TX, US) in Tris-buffered 
saline containing 0.05 % Tween-20 (0.05 % TBS-T; Sigma, 
St. Louis, MO, US) at room temperature for 2  h. Mem-
branes were probed with primary antibodies purchased 
from Cell Signaling (Danvers, MA, US) overnight at 4 °C 
(markers of mTOR pathway and its upstream modula-
tors: phospho-mTOR [Ser2448]—#2971; mTOR—#2972; 
Fig. 1 Experimental protocol. NG normoglycemia, AHG acute hyperglycemia, Isch ischemia only group, RIPerC remote ischemic perconditioning, 
nTyr 3–nitrotyrosine, TTC triphenyltetrazolium chloride
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phospho-S6 [Ser235/236]—#2211; ribosomal S6—#2317; 
phospho-AKT [Ser473]—#9271; AKT—#9272; phospho-
AMP-activated protein kinase α [AMPKα; Thr172]—
#2535; AMPKα—#5831; phospho- extracellular 
signal-regulated kinase 1/2 [Erk1/2; Thr202/Tyr204]—
#9106; Erk1/2—#9107; well-established markers of 
autophagy: microtubule-associated protein 1 light chain 
3 A/B [LC3A/B]—#4108; beclin-1—#3495; SQSTM1/
p62—#5114; phospho-UNC-51-like kinase 1 [p-ULK1; 
Ser555]—#5869; ULK1—#4773; autophagy-related 
gene 7 [ATG7]—#8558; Bcl-2/E1B-interacting protein 3 
[BNIP3]—#3769; loading control: GAPDH—#5174), and 
with corresponding horseradish peroxidase-conjugated 
secondary antibodies (Cell Signaling, Danvers, MA, US) 
for 2 h at room temperature. Signals were detected with 
an enhanced chemiluminescence kit (Bio-Rad, Hercules, 
CA, US) by Chemidoc XRS+ (Bio-Rad, Hercules, CA, 
US). Antibodies detecting phosphorylated epitopes were 
removed with Pierce Stripping Buffer (Thermo Fisher Sci-
entific, Waltham, MA, US) before incubation with anti-
bodies detecting the total protein.
Triton X‑100‑insoluble SQSTM1/p62 Western blot
Left ventricular tissue was homogenized with Tissue-
Lyser (Qiagen, Venlo, Netherlands) in a homogenation 
buffer containing 50  mM Tris, 150  mM NaCl, 1  mM 
EDTA, 10 % glycerol and 2 % Triton X-100 (pH 8.0) sup-
plemented with protease inhibitor (Roche, Basel, Swit-
zerland), sodium fluoride (Sigma, St. Louis, MO, US) 
and PMSF (Sigma, St. Louis, MO, US). Homogenates 
were centrifuged (10,000×g, 10  min, 4  °C) supernatant 
was carefully removed and discarded. Pellet was washed 
with the abovementioned homogenation buffer once 
again (10,000×g, 10 min, 4 °C). Then pellets were resus-
pended in sample buffer containing 62.5 mM Tris–HCl, 
5  % glycerol and 1.3  % SDS. Protein concentration of 
the homogenates was measured by Bicinchoninic Acid 
Assay kit (Thermo Fisher Scientific, Waltham, MA, US). 
Equal amount of protein (20  µg) was loaded, separated 
and processed under reducing conditions as described 
above.
Statistical analysis
Data was expressed as mean ±  standard error of mean. 
Student’s t test and two-way ANOVA with LSD as a post 
hoc test were used for statistical analyses in most cases, 
Kaplan–Meier estimation for evaluating mortality data, 
and Kruskal–Wallis analysis for analyzing scores. Statis-
tical significance was accepted if p < 0.05.
Results
Acute hyperglycemia abolishes the protective effect 
of RIPerC
To investigate the effect of acute hyperglycemia on the 
efficacy of RIPerC, acute hyperglycemia was induced 
with a 50  % dextrose infusion during in  vivo ischemia/
reperfusion experiments. Blood glucose level was sig-
nificantly elevated due to dextrose perfusion in both 
AHG  +  Isch and AHG  +  RIPerC groups compared to 
the corresponding NG group from at least the 15th min 
of perfusion [Table  1, preliminary results showed that 
acute hyperglycemia developed in 5 min (17.2 ± 1.8 mM, 
n =  4)]. Although baseline blood glucose appears to be 
higher than reported normal levels, it should be noted 
that baseline plasma glucose levels were measured in 
non-fasting animals which might have resulted in this 
relatively elevated, but still normoglycemic blood glucose 
level [20]. Elevated blood glucose levels did not influence 
the heart rate and blood pressure of the rats (Table  2). 
Until the end of the ischemic period, mortality rate was 
11.1 % (1), 9.1 % (1), 30.0 %, (3) and 14.3 % (1), whereas 
total mortality was 0.0 % (0), 10.0 % (1), 14.3 %, (1) and 
16.7  % (1) during reperfusion in Isch, RIPerC, AHG + 
Isch and AHG + RIPerC groups, respectively. Mortality 
was not significantly different between groups.
Infarct size was significantly smaller in NG  +  RIP-
erC group compared to NG  +  Isch (24.65  ±  7.45 vs. 
46.27 ±  5.31  %; p  <  0.05; n =  7–10; Fig.  2), while RIP-
erC failed to decrease infarct size in AHG  +  RIPerC 
group when compared to AHG  +  Isch (52.76  ±  3.80 
vs. 54.19  ±  4.07  %; p  >  0.05; n  =  5–6; Fig.  2). Fur-
thermore, acute hyperglycemia per se did not aggra-
vate cardiac necrosis (Fig.  2). There was no difference 
Table 1 Blood glucose (mM) is elevated in acute hyperglycemia
NG normoglycemia, AHG acute hyperglycemia, Isch ischemia only group, RIPerC remote ischemic perconditioning
*p < 0.05 vs. corresponding time point of NG + Isch group
# p < 0.05 vs. corresponding time point of NG + RIPerC group. n = 5–10
0′ 15′ 30′ 70′ 190′
NG 8.6 ± 0.3 6.8 ± 0.2 8.4 ± 0.7 NG + Isch 9.2 ± 0.7 9.1 ± 1.1
NG + RIPerC 9.2 ± 0.6 8.5 ± 0.5
AHG 8.5 ± 0.3 17.7 ± 1.0* 21.3 ± 2.1* AHG + Isch 18.0 ± 1.3* 18.6 ± 0.6*
AHG + RIPerC 19.9 ± 1.4# 18.4 ± 0.6#
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between the areas at risk of various groups (NG +  Isch: 
51.58 ± 1.65 %; NG + RIPerC: 45.13 ± 2.99; AHG + Isch: 
49.44 ± 3.90; AHG + RIPerC: 43.64 ± 2.25 %; p > 0.05; 
n = 5–10).
AHG exacerbates the incidence and duration 
of arrhythmias during ischemia
Arrhythmia analysis revealed that AHG compared to 
NG significantly increased the incidence and duration 
of arrhythmias during the whole myocardial ischemic 
period, but arrhythmia incidence and duration were not 
different during reperfusion (Table 3).
RIPerC did not alter arrhythmia scores from the time 
point it was applied, as compared to Isch group (Table 3). 
Furthermore, RIPerC did not decrease arrhythmia scores 
during acute hyperglycemia compared to AHG + RIPerC 
(Table 3).
Acute hyperglycemia increases nitrative stress
Increased oxidative and nitrative stresses are often impli-
cated in the disruption of cardioprotective interventions. 
Therefore, 3-nitrotyrosine content, a marker of nitrative 
stress was measured in hearts of NG and AHG rats at 35′. 
Cardiac 3-nitrotyrosine was significantly elevated due 
to acute hyperglycemia (0.87 ±  0.01 vs. 0.50 ±  0.04  µg 
3-nitrotyrosine/mg protein; p < 0.05; n = 8; Fig. 3).
Acute hyperglycemia activates mTOR pathway
Since the oxidative and nitrative stress have been pre-
viously shown to interact with mTOR pathway [21], we 
evaluated the expression and/or phosphorylation of 
mTOR pathway associated proteins. The phosphorylation 
of mTOR (Ser2448) and S6 (Ser235/236) was significantly 
elevated (Fig.  4a, b), which indicates that the activity of 
mTOR complex I was increased in AHG group. Phos-
phorylation of AKT at site Ser473 was also significantly 
elevated in AHG group (Fig. 4c), however, other mTOR 
regulators, such as phosphorylated AMPKα (Thr172) and 
Erk1/2 (Thr202/Tyr204) were unchanged in AHG group 
as compared to NG (Fig. 4d, e).
Acute hyperglycemia does not influence autophagy
Since oxidative/nitrative stress and mTOR pathway have 
been shown to interact with autophagy, expression and/
or phosphorylation of autophagy-related proteins were 
assessed in NG and AHG groups. LC3II/LC3I ratio 
was significantly decreased due to acute hyperglycemia 
(Fig. 5a), however, other autophagy-related proteins such 
as Beclin-1, total and Triton X-100-insoluble SQSTM1/
p62, phospho-ULK1 (Ser555), ATG7 and BNIP3 were 
unchanged in AHG group (Fig. 5b–g).
Discussion
We have demonstrated for the first time in the literature 
that acute hyperglycemia with no preceding diabetes 
mellitus abolished the infarct size limiting effect of RIP-
erC in an in vivo rat model with acute coronary occlusion 
Table 2 Acute hyperglycemia does not influence heart rate (HR) and mean arterial blood pressure (MABP)
NG normoglycemia, AHG acute hyperglycemia, Isch ischemia only group, RIPerC remote ischemic perconditioning
p > 0.05. n = 5–10
0′ 15′ 30′ 40′ 60′ 80′ 100′ 120′ 140′ 160′ 180′
HR (1/min)
 NG 428 ± 10 409 ± 12 415 ± 9 NG + Isch 438 ± 15 422 ± 12 430 ± 13 419 ± 10 411 ± 12 411 ± 18 425 ± 20 421 ± 14
NG + RIPerC 419 ± 15 432 ± 14 418 ± 14 420 ± 8 428 ± 10 416 ± 9 427 ± 9 428 ± 13
 AHG 420 ± 12 417 ± 8 403 ± 9 AHG + Isch 430 ± 15 425 ± 8 437 ± 11 422 ± 5 416 ± 5 415 ± 9 419 ± 8 410 ± 6
AHG + RIPerC 410 ± 8 435 ± 10 409 ± 12 414 ± 16 408 ± 11 415 ± 11 406 ± 18 396 ± 18
MABP (mmHg)
 NG 111 ± 5 114 ± 7 114 ± 6 NG + Isch 116 ± 13 110 ± 10 109 ± 10 110 ± 9 109 ± 9 107 ± 8 108 ± 7 106 ± 11
NG + RIPerC 111 ± 6 118 ± 6 109 ± 7 105 ± 7 107 ± 7 100 ± 8 105 ± 7 106 ± 7
 AHG 112 ± 7 125 ± 8 119 ± 8 AHG + Isch 107 ± 8 103 ± 11 110 ± 7 105 ± 7 106 ± 7 101 ± 9 105 ± 6 108 ± 6
AHG + RIPerC 98 ± 16 118 ± 13 106 ± 11 116 ± 10 109 ± 13 113 ± 11 106 ± 13 103 ± 12
Fig. 2 Acute hyperglycemia abolishes cardioprotective effect of RIP‑
erC. Infarct size related to the AAR. *p < 0.05 vs. NG + Isch. #p < 0.05 
vs. NG + RIPerC. n = 5–10. NG normoglycemia, AHG acute hypergly‑
cemia, Isch ischemia only group, RIPerC remote ischemic percondi‑
tioning, IS infarct size, AAR area at risk
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and reperfusion. Furthermore, we have shown here that 
acute hyperglycemia did not influence autophagy, but 
increased nitrative stress in the heart plausibly through 
the activation of the AKT-mTOR pathway.
The major novelty of this study is that experimentally 
induced acute hyperglycemia with no preceding diabetes 
diminishes cardioprotective effect of RIPerC. This finding 
supports previous observations showing that other forms 
of cardioprotection may be affected by acute hypergly-
cemia. Kersten et  al. described that cardioprotection by 
ischemic preconditioning is absent during acute hyper-
glycemia in dogs [13]. Similarly, acute hyperglycemia 
diminished cardioprotection conferred by isoflurane-
induced preconditioning, however, it was reversible by 
increasing the minimum alveolar concentration in dogs 
[12]. It has been recently shown that hyperglycemia at 
admission does not deteriorate RIPerC, however, in this 
patient cohort, the presence of comorbidities, such as 
treated or untreated diabetes, have not been reported 
[22]. Although we showed here that acute hyperglycemia 
did not influence the extent of myocardial infarct size, 
a few studies have reported that acute hyperglycemia 
without any pre-exisisting pathophysiological conditions 
aggravate myocardial infarct size [13, 23, 24]. However, 
the majority of publications concludes that acute hyper-
glycemia per se do not change infarct size [25–27]. The 
seemingly contradictory findings may have been the 
result of applying different glucose concentrations, since 
reports suggesting harmful effects of acute hyperglyce-
mia applied consistently higher glucose concentrations 
(i.e., over 30 mM).
The underlying mechanism of the loss of RIPerC-
induced cardioprotection by acute hyperglycemia is 
not fully understood. Increased oxidative and nitrative 
stresses are implicated in the disruption of cardioprotec-
tive interventions by metabolic co-morbidities [2, 28–32], 
while conditioning stimuli such as RIC alleviates nitrative 
stress [28]. It was shown here that nitrative stress was 
also increased in acute hyperglycemia in rat heart in vivo, 
and similar results have been shown in isolated rat hearts 
perfused with hyperglycemic solution [33]. These find-
ings clearly signal the pivotal role of excessive nitrative 
stress in the loss of cardioprotection in disturbed glucose 
homeostasis.
Oxidative and nitrative stresses have also been shown 
to directly disrupt autophagy (see for review: [34]). 
Therefore, we assessed cardiac autophagy and its regu-
latory pathways in acute hyperglycemia. However, we 
found that autophagy was unlikely to be disrupted, as 
only LC3II/LC3I ratio was significantly reduced, but 
other autophagy-related parameters were not. Although 
cardiac autophagy was not modulated, its most impor-
tant regulator the mTOR pathway was largely activated 
by acute hyperglycemia. Since it has been shown that the 
inhibition of mTOR by rapamycine elicits cardioprotec-
tive effect in vivo [35, 36], and that RIC, while protecting 
the myocardium against ischemia, downregulates mTOR 
[37]. We hypothesize that the upregulated mTOR path-
way might be responsible for this loss of cardioprotection 
Table 3 Acute hyperglycemia exacerbates the incidence and duration of arrhythmias during ischemia
NG normoglycemia, AHG acute hyperglycemia, Isch ischemia only group, RIPerC remote ischemic perconditioning
*p < 0.05 vs. corresponding time point of NG + Isch group
#p < 0.05 vs. corresponding time point of NG + RIPerC group. n = 5–10
0–35′ 35–45′ 45–75′ 75–195′
Arrhythmia incidence scores
 NG 4.87 ± 1.28 NG + Isch 1.79 ± 0.73 2.47 ± 0.69 8.10 ± 3.01
NG + RIPerC 3.09 ± 1.57 3.03 ± 0.98 6.56 ± 1.12
 AHG 1.99 ± 0.45 AHG + Isch 14.06 ± 3.34* 23.17 ± 2.1* 8.79 ± 1.97
AHG + RIPerC 10.69 ± 6.68 12.88 ± 6.87# 7.72 ± 3.19
Arrhythmia duration scores
 NG 3.65 ± 0.84 NG + Isch 1.59 ± 0.61 2.18 ± 0.57 7.58 ± 2.92
NG + RIPerC 1.88 ± 0.73 2.18 ± 0.67 4.98 ± 0.82
 AHG 1.99 ± 0.45 AHG + Isch 7.49 ± 1.58* 14.46 ± 2.84* 8.27 ± 1.95
AHG + RIPerC 4.08 ± 1.43 8.98 ± 3.62# 7.71 ± 3.18
Fig. 3 Acute hyperglycemia increases cardiac nitrative stress. 3‑nitro‑
tyrosine content of hearts of NG or AHG rats. *p < 0.05 vs. NG. n = 8. 
NG normoglycemia, AHG acute hyperglycemia
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by RIPerC in acute hyperglycemia. Furthermore, it was 
also been previously shown that under nutrient excess 
and oxidative stress, such as that seen in hyperglycemia, 
the mTOR pathway and its upstream modulator AKT 
are increasingly activated [38–40]. It is well established 
that activation of AKT upon reperfusion plays a central 
role in the mediation of cardioprotection conferred by 
ischemic pre-, post-, and remote conditioning (see for 
review: [41]). However, the cardioprotective effect of 
AKT activation before cardiac ischemia is controversial. 
Although genetic activation of AKT (24 h or 48 h prior 
to ischemia) protected the heart from ischemic insults 
[42, 43], more acute activation of AKT by SC79 and 
chronic AKT activation in ob/ob mice prior to ischemia 
did not confer protection against ischemia/reperfusion 
injury [44, 45]. We also demonstrated here that acute 
hyperglycemia-induced AKT activation prior to myocar-
dial ischemia did not alter infarct size. These discrepan-
cies could be explained by the fact that genetic activation 
of AKT induces an overwhelming alteration in cardiac 
gene expression profile [46] which might have not yet 
developed in our acute experiments. Moreover, we also 
showed that despite the acute hyperglycemia-induced 
activation of AKT, cardioprotective effects of remote 
ischemic perconditioning are lost. Similarly, it was pre-
viously reported that AKT activation prior to ischemia 
significantly interferes with protective stimuli, such as 
ischemic pre- and postconditioning [45, 47]. Therefore, 
one may conclude that the timing and the method of acti-
vation of AKT can profoundly influence its role in car-
dioprotection. Furthermore, AKT has a central role in 
the insulin signalling cascade and in the modulation of 
the mTOR pathway [48]. Here we evidenced an increased 
AKT in acute hyperglycemia, however, others found 
opposing trends in various cellular and in  vivo models 
of hyperglycemia [26, 49, 50]. This discrepancy might be 
attributed to the substantial difference in the activation 
state of insulin signalling between model systems (i.e., 
missing insulin in STZ-treated animals or limited sup-
ply of insulin in cell cultures). Nevertheless, our current 
results demonstrate that AKT activation in an in  vivo 
model with intact insulin and glucose homeostasis is det-
rimental on cardioprotection.
Limitations
Here we evaluated the effect of acute hyperglycemia 
on the myocardium without ischemia or RIPerC. It is 
well established that ischemia and cardioprotective 
Fig. 4 Acute hyperglycemia activates mTOR pathway. a–e Protein expression and/or phosphorylation of various mTOR‑related proteins in the left 
ventricle. *p < 0.05 vs. NG. n = 7–9. NG normoglycemia, AHG acute hyperglycemia
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interventions significantly and dynamically influence 
autophagy and nitrative stress [28, 51, 52]. Thus, if such 
parameters are assessed after ischemia, i.e., in cardiac tis-
sues with different level of exposure to ischemic insult, 
corresponding ischemic, border and remote zones, 
it would be unclear whether a possibly deteriorated 
autophagy and increased nitrative stress are causes or 
consequences of ischemia and/or reperfusion injury. Nev-
ertheless, such experiments are still warranted to clarify 
the role of the mTOR pathway, autophagy and nitrative 
stress in the loss of RIPerC in acute hyperglycemia.
Conclusions
In conclusion, here we have shown evidence for the first 
time in the literature that the cardioprotective effect of 
RIPerC is lost in acute hyperglycemia. The mechanism of 
this phenomenon may involve an acute hyperglycemia-
induced increase of nitrative stress and activation of the 
AKT-mTOR pathway, but not the disruption of cardiac 
autophagy. This data suggests that the efficacy of RIP-
erC might be compromised in clinical settings with acute 
hyperglycemia.
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